The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports
Neuroscientist With Research Program Joins Biotech's SAB
ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program.Co. Meets Goals in COVID Drug Trial
Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data.Pharma to Test if DMT Helps Brain Regain Function Post Stroke
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman.Possible Treatment for CRC Shows Promise
Research Report
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report.
Bone Cancer Drug Meets Goals, Stocks Rise
Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size.‘Strong Data’ Expected From Todos Medical Data Lock
Contributed Opinion
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir.
Fourth COVID-19 Vaccine Shot Shown Less Effective
Research Report
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report.
FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen
Research Report
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report.
First NSCLC Patient Dosed With Trial Therapeutic
Research Report
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report.
Fund Triples Holding of Drug Repurposing Firm
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report.Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B
Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met.Derm Biopharma Named Top Growth Pick For 2022
Research Report
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.
This Pharmaceutical Company Has a Brilliant Concept
Contributed Opinion
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.
Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial
Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study.Ph1 Trial Results of Dementia Drug Positive
Research Report
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.
Biotech Co. Partners With Life Sciences Firms
Research Report
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.
Enrollment Done for COVID-19 Drug Trial
Research Report
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.
2022 to Be Catalyst Rich for Biopharma
Research Report
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.
Co.'s samRNA Vaccines Protect Better Against COVID Variants
Research Report
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.
AI Driven Drug Firm Partners With Merck
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.Co. Partners to Test New Cancer Vaccines
Research Report
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.
Co. Plans to Make 100M Rapid COVID Tests Monthly
Research Report
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.